recombinant Tiantan vaccinia HIV vaccine

Recombinant Tiantan vaccinia HIV vaccine (rTV-HIV) is a viral vector vaccine candidate developed for the prevention and treatment of HIV-1 infection. It utilizes the Tiantan strain of the vaccinia virus, which was historically employed in China's smallpox eradication program, as a delivery vehicle. The vector is genetically engineered to express HIV-1 antigens, typically including the Gag, Pol, and Env proteins, to induce robust cellular and humoral immune responses. In clinical trials, it is frequently evaluated as part of a heterologous prime-boost strategy, often following priming with a DNA-based HIV vaccine (DNA-HIV). This approach aims to broaden and intensify the T-cell response against HIV-1. The development of this vaccine has been primarily supported by the Chinese Center for Disease Control and Prevention and clinical partners like Beijing Youan Hospital.

Other names

recombinant vaccinia virus Tiantan strain HIV vaccineTiantan vaccinia-based HIV vaccine